Biotie starts clinical study with phosphodiesterase 4 inhibitor
ELB353
(Thomson Reuters ONE) - BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE September 14, 2009at 1 p.m.Biotie starts clinical study with phosphodiesterase 4 inhibitorELB353Biotie has started a clinical trial with its phosphodiesterase 4(PDE4) inhibitor ELB353, having received the prerequisite regulatoryand ethical clearances for the clinical trial application.The study will be conducted within the European Union and willevaluate the safety, tolerability, pharmacodynamics andpharmacokinetics of repeated doses of oral ELB353 in up to 48 healthyvolunteers. The study is expected to provide proof of pharmacodynamicactivity in humans, corroborate the safety profile and establish doseranges for further therapeutic studies. Results are expected in thefirst half of 2010.ELB353 is a once-daily, oral PDE4 inhibitor with therapeuticpotential in chronic inflammatory disorders, particularly in chronicobstructive pulmonary disease (COPD), a serious disorder with majorunmet medical need.Turku, September 14, 2009Biotie Therapies Corp.Timo VeromaaPresident and CEOFor further information, please contact:Antero Kallio, Chief Medical OfficerTel. +358 2 274 8900, e-mail: antero.kallio(at)biotie.comVirve Nurmi, Investor Relations Managertel. +358 2 274 8911, e-mail: virve.nurmi(at)biotie.comwww.biotie.comDistribution:NASDAQ OMX Helsinki LtdMain Mediawww.biotie.comBiotie Therapies Corp.Biotie is a drug discovery and development company focused on centralnervous system and inflammatory diseases. It has a broad range ofinnovative small molecule and biological drug candidates at differentstages of clinical and pre-clinical development. Biotie's productsaddress diseases with high unmet medical need and significant marketpotential, including addiction and psychotic disorders, rheumatoidarthritis, psoriasis and chronic obstructive pulmonary disease(COPD). The most advanced product, nalmefene for alcohol dependence,is currently in phase III clinical development by licensing partnerH. Lundbeck A/S.The commercial value of the pipeline has been demonstrated throughexisting alliances with top-tier global pharmaceutical companies suchas Lundbeck, Roche and Wyeth. Biotie has operations in Turku, Finlandand Radebeul, Germany.Biotie shares are listed on NASDAQ OMX Helsinki Ltd.For more information, please refer to www.biotie.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 14.09.2009 - 12:01 Uhr
Sprache: Deutsch
News-ID 5778
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 340 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biotie starts clinical study with phosphodiesterase 4 inhibitor
ELB353"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotie Therapies Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
